Dalle J H
Unité protégée A, clinique de pédiatrie, hôpital Jeanne-de-Flandre, CHU de Lille, 59037 Lille cedex France.
Arch Pediatr. 2005 Mar;12(3):298-304. doi: 10.1016/j.arcped.2004.12.011.
Since 1988, allogeneic cord blood transplantations have been used in the hematology and oncology area. Cord blood banks, either public or from non-profit corporations, opened in several countries. They organized themselves into a world-wide network permitting broad and quick graft availability all over the world. Cryopreservation modalities and biological safety were strongly defined according to laboratory good practices. More recently, in the United States, Canada and some European and Asian countries, commercial companies created for-profit cord blood banks. They offer families the possibility of privately storing the cord blood of their children. Then, if a child gets sick and needs a hematopoietic stem cell transplantation, it is possible to use the cord blood for an autograft. These companies present this service, relatively expensive for the families, as a true biological insurance. Also, they capitalize on families' hopes that scientific progress will increase cord blood autografts and other stem cell medical applications. In this work, we review available scientific data, ethical considerations and laws that can contribute to an informed reflection.
自1988年以来，异基因脐带血移植已应用于血液学和肿瘤学领域。在几个国家，公共或非营利性公司的脐带血库相继开放。它们组成了一个全球网络，使世界各地能够广泛、快速地获得移植物。根据实验室良好规范，对冷冻保存方式和生物安全性进行了严格界定。最近，在美国、加拿大以及一些欧洲和亚洲国家，商业公司设立了营利性脐带血库。它们为家庭提供了私下储存孩子脐带血的可能性。这样，如果孩子生病需要进行造血干细胞移植，就可以使用脐带血进行自体移植。这些公司将这项对家庭来说相对昂贵的服务作为一种真正的生物保险来推销。此外，它们利用了家庭对科学进步将增加脐带血自体移植及其他干细胞医学应用的期望。在这项工作中，我们回顾了有助于进行明智思考的现有科学数据、伦理考量和法律。
